Introduction {#section5-2050312118772475}
============

Platinum-based compounds that are widely used in the treatment of testicular, ovarian, breast, cervical, bladder, and lung cancers include cisplatin, carboplatin, oxaliplatin, and nedaplatin.^[@bibr1-2050312118772475][@bibr2-2050312118772475]-[@bibr3-2050312118772475]^ These compounds cause adverse events (AEs) such as nephrotoxicity, gastrointestinal toxicity, myelosuppression, ototoxicity, and neurotoxicity. Although platinum-based compounds have some structural similarities, their AE profiles differ. Cisplatin causes severe renal tubular damage and reduces glomerular filtration.^[@bibr3-2050312118772475]^ One of the dose-limiting AEs of cisplatin is nephrotoxicity. Among the platinum-based compounds approved for use, cisplatin causes the most severe nausea and vomiting, which are usually prevented or managed with current antiemetic regimens.^[@bibr4-2050312118772475],[@bibr5-2050312118772475]^ Carboplatin is a second-generation platinum-based drug. It is a prodrug of cisplatin and a more stable platinum-based analog than cisplatin.^[@bibr6-2050312118772475]^ Carboplatin-treated patients experience lower incidences of nausea, vomiting, and renal toxicity than cisplatin-treated patients.^[@bibr6-2050312118772475],[@bibr7-2050312118772475]^ Nedaplatin is significantly less nephrotoxic than cisplatin or carboplatin.^[@bibr8-2050312118772475],[@bibr9-2050312118772475]^ Oxaliplatin is a third-generation platinum drug that is generally used for standard treatment together with 5-fluorouracil/leucovorin.^[@bibr10-2050312118772475]^ The incidence of neurotoxicity resulting from the co-therapy increases with the addition of oxaliplatin.^[@bibr10-2050312118772475]^ Therefore, the benefits of these frequently prescribed drugs are compromised by the severe AEs they cause.

The analysis of spontaneous reporting systems (SRSs) has served as a valuable tool in post-marketing surveillance that reflects the realities of clinical practice. The Pharmaceuticals and Medical Devices Agency (PMDA), a regulatory authority in Japan, receives voluntary AE reports directly from healthcare professionals and consumers, and has released the Japanese Adverse Drug Event Report (JADER) database as an SRS. The JADER database files are openly available on the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). Several pharmacovigilance indices, such as reporting odds ratio (ROR), have been developed for the detection of drug-associated AEs.^[@bibr11-2050312118772475]^ It has been proposed that the time-to-onset analysis using the Weibull shape parameter (WSP) of AEs could be a useful tool for signal detection.^[@bibr12-2050312118772475][@bibr13-2050312118772475][@bibr14-2050312118772475][@bibr15-2050312118772475][@bibr16-2050312118772475][@bibr17-2050312118772475][@bibr18-2050312118772475]--[@bibr19-2050312118772475]^ Furthermore, association rule mining has been proposed as a new analytical approach for discovering undetected relationships such as the possible risk factors between variables in large databases.^[@bibr18-2050312118772475][@bibr19-2050312118772475][@bibr20-2050312118772475][@bibr21-2050312118772475]--[@bibr22-2050312118772475]^

In this study, we aimed to assess renal impairment (RI) caused by platinum-based compounds by analyzing data from the JADER database. Analyses of the time to onset of RI using the JADER database are rare, and to the best of our knowledge, this is the first study to use association rule mining to detect the association rules between platinum-based compounds and RI.

Materials and methods {#section6-2050312118772475}
=====================

Data from April 2004 to November 2016 were extracted from the JADER database on the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). The data comprised cases mainly spontaneously reported by pharmaceutical industries, healthcare professionals, and consumers. All data from the JADER database were fully anonymized by the PMDA before we used them. The database consists of four tables: patient demographic information such as sex, age, and reporting year (DEMO); drug information such as drug name and start and end dates of administration (DRUG); AEs and onset date (REAC); and primary disease (HIST). We built a relational database that integrated the four tables using FileMaker Pro 12 software (FileMaker, Inc., Santa Clara, CA, USA). Four platinum-based compounds (cisplatin, oxaliplatin, carboplatin, and nedaplatin) were assessed in the analysis. In case of drug involvement, drugs reported as the DRUG file contained the following role codes assigned to each drug: suspected drug, concomitant drug, and interacting drugs (*higiyaku*, *heiyouyaku*, and *sougosayou* in Japanese, respectively). In this study, we analyzed suspected drug records.

Preferred terms (PTs) from the Medical Dictionary for Regulatory Activities (<http://www.meddra.org>/, version 19.0) were used to define medical terminologies in the JADER database. The following six PTs were used to extract cases of platinum compound--induced RI from the JADER database: "acute kidney injury," "renal impairment," "renal failure," "renal disorder," "renal function test abnormal," and "renal tubular disorder."

We used ROR to analyze the association between the use of platinum-based compounds and RI. ROR represents the odds of a specific AE caused by the drug of interest compared to the odds of a specific AE caused by all other drugs, and is calculated based on the two-by-two contingency table ([Figure 1](#fig1-2050312118772475){ref-type="fig"}).^[@bibr23-2050312118772475]^ RORs are expressed as point estimates with 95% confidence intervals (CIs). The signal was considered positive when the lower limit of 95% CI was \>1 and the number of reports was ≥2.^[@bibr23-2050312118772475],[@bibr24-2050312118772475]^

![Two-by-two contingency table for analysis.](10.1177_2050312118772475-fig1){#fig1-2050312118772475}

Time-to-onset duration was calculated from the time of the patient's first prescription to the occurrence of RI. The records with completed AE occurrence and prescription start date were used for the time-to-onset analysis. It was necessary to consider right truncation when evaluating the time to onset of AEs. We determined an analysis period of 90 days after the start of administration to focus on the onset of AEs within 3 months after the patients' first prescription. The median duration, quartiles, and WSPs were used to evaluate the time-to-onset data. The scale parameter α of the Weibull distribution determines the scale of the distribution function. A larger scale value (α) stretches the distribution, whereas a smaller scale value (α) shrinks the data distribution. The shape parameter β of the Weibull distribution determines the shape of the distribution function. Larger and smaller shape values produce left- and right-skewed curves, respectively.

In the analysis of SRS, the shape parameter β of the Weibull distribution was used to indicate the level of hazard over time without a reference population. When β was 1 (random failure type), the hazard was considered to be constant over time. When β was \>1, the hazard was considered to increase over time (wear-out failure type). In contrast, when β was lower than 1, the hazard was considered to decrease over time (initial failure type).^[@bibr12-2050312118772475][@bibr13-2050312118772475][@bibr14-2050312118772475][@bibr15-2050312118772475][@bibr16-2050312118772475][@bibr17-2050312118772475][@bibr18-2050312118772475]--[@bibr19-2050312118772475]^

The time-to-onset analysis was performed using the JMP software version 11 (SAS Institute, Cary, NC, USA).

Association rule mining is focused on finding frequent co-occurring associations among a collection of items. Given a set of transactions ***T*** (each transaction is a set of items), an association rule can be expressed as *X* \[the antecedent (left-hand side, lhs) of rule:\] → *Y* \[the consequent of the rule (right-hand side, rhs) of rule:)\], where *X* and *Y* are mutually exclusive sets of items.^[@bibr25-2050312118772475]^ *Support*, *confidence*, and *lift* were used as indicators to evaluate the association rule. *Support* expresses how often the itemset appears in a single transaction in the dataset. The *support* was measured as

$$Support = \ P\left( {X \cap Y} \right) = \frac{\left\{ X \cap Y \right\}}{\left\{ D \right\}}$$

where *D* is total number of transactions in the database.

*Confidence* is the proportion of the cases covered by the lhs of the rule that was covered by the rhs, which provides an estimate of the conditional probability *P*(*Y*\|*X*). *Confidence* measures the reliability of the interference made by a rule. The formula for calculating *confidence* is as follows

$$Confidence = \ \frac{P\left( {X \cap Y} \right)}{P\left( X \right)}$$

*Lift* is the ratio between the *confidence* of the rule and the *support* of the itemset in the consequent of the rule. It is calculated as follows

$$Lift = \ \frac{P\left( {X \cap Y} \right)}{P\left( X \right)\ P\left( Y \right)}$$

When the *lift* is 1, \>1, or \<1, then *X* and *Y* are independent, positively correlated, or negatively correlated, respectively.

The association rule mining was performed using the *apriori* function of the *arules* library in the *arules* package of the R software (version 3.3.3).^[@bibr26-2050312118772475]^ The first step of the *apriori* algorithm searches for itemsets that have more than minimum *support* as predetermined by the researcher.^[@bibr20-2050312118772475],[@bibr27-2050312118772475]^ In the second step, rules are generated by selecting the itemsets that were based on a threshold of *confidence* from those found in the first step. Because all possible rules are enumerated from a large database, the first step is a bottleneck. It is important to note the parameter of the maximum size of mined frequent itemsets (*maxlen*; maximum length of itemset/rule: a parameter in the *arules* package), as longer association rules are mined if *maxlen* is set to a higher value. Therefore, to extract association rules efficiently, the thresholds of the optimized *support, confidence*, and *maxlen* are defined depending on factors such as the size of data, the number of items, and the purpose of the research. Furthermore, subset selection and sorting a set of associations can be analyzed even if the number of rules is huge. We applied subset selection with RI and platinum-based compounds. In this study, we defined the minimum *support* and *confidence* thresholds as 0.0001 and 0.05, respectively, and *maxlen* was restricted to 3 ([Supplementary 1 Table](http://journals.sagepub.com/doi/suppl/10.1177/2050312118772475)). In the preliminary calculation, the number of extracted rules defined by *support* (0.0001), *confidence* (0.05), and *maxlen* (3), using subset selection of RI and platinum-based compounds, was 31 ([Supplementary 1 Table](http://journals.sagepub.com/doi/suppl/10.1177/2050312118772475)). Using subset selection of RI and platinum-based compounds, the number of extracted rules defined by *support* (0.00001), *confidence* (0.005), and *maxlen* (3) was 502 ([Supplementary 1 Table](http://journals.sagepub.com/doi/suppl/10.1177/2050312118772475)).

Results {#section7-2050312118772475}
=======

The JADER database contained 430,587 reports from April 2004 to November 2016. The number of cases of RI incidences was 14,872, and the cases related to the use of platinum-based compounds are summarized in [Table 1](#table1-2050312118772475){ref-type="table"}. The table lists the 50 largest PTs in the reporting of the number of AEs. Cisplatin caused the highest number of RI events ("renal impairment" and "acute kidney injury") among the four platinum-based compounds studied. The RORs (95% CI) for RI following the use of cisplatin, oxaliplatin, carboplatin, and nedaplatin were 2.7 (2.5--3.0), 0.6 (0.5--0.7), 0.8 (0.7--1.0), and 1.3 (0.8--2.1), respectively ([Table 2](#table2-2050312118772475){ref-type="table"}). The lower limit of the ROR (95% CI) for cisplatin was \>1.

###### 

Adverse events of cisplatin, oxaliplatin, carboplatin, and nedaplatin.

![](10.1177_2050312118772475-table1)

  Cisplatin                                      Oxaliplatin      Carboplatin                              Nedaplatin                                                                                                              
  ---------------------------------------------- ---------------- ---------------------------------------- ---------------- ---------------------------------------- -------------- ---------------------------------------------- -------------
  Cases related to cisplatin                     13,231 (100.0)   Cases related to oxaliplatin             11,797 (100.0)   Cases related to carboplatin             7822 (100.0)   Cases related to nedaplatin                    657 (100.0)
  Neutrophil count decreased                     722 (5.5)        Neutropenia                              1543 (13.1)      Neutrophil count decreased               462 (5.9)      Neutrophil count decreased                     54 (8.2)
  Neutropenia                                    709 (5.4)        Leukopenia                               1022 (8.7)       Platelet count decreased                 453 (5.8)      White blood cell count decreased               42 (6.4)
  White blood cell count decreased               616 (4.7)        Interstitial lung disease                574 (4.9)        White blood cell count decreased         368 (4.7)      Platelet count decreased                       39 (5.9)
  Platelet count decreased                       515 (3.9)        Neutrophil count decreased               566 (4.8)        Interstitial lung disease                287 (3.7)      Neutropenia                                    39 (5.9)
  Febrile neutropenia                            493 (3.7)        Anaphylactic shock                       502 (4.3)        Neutropenia                              270 (3.5)      Thrombocytopenia                               33 (5.0)
  Anorexia                                       469 (3.5)        Hemoglobin decreased                     422 (3.6)        Febrile neutropenia                      252 (3.2)      Interstitial lung disease                      25 (3.8)
  Leukopenia                                     433 (3.3)        Neuropathy peripheral                    370 (3.1)        Anaphylactic shock                       199 (2.5)      Diarrhea                                       24 (3.7)
  Diarrhea                                       372 (2.8)        Thrombocytopenia                         357 (3.0)        Bone marrow failure                      172 (2.2)      Anaphylactic shock                             23 (3.5)
  Anemia                                         328 (2.5)        Anorexia                                 318 (2.7)        Pneumonia                                157 (2.0)      Febrile neutropenia                            22 (3.3)
  Nausea                                         327 (2.5)        Diarrhea                                 290 (2.5)        Anemia                                   157 (2.0)      Bone marrow failure                            19 (2.9)
  Hemoglobin decreased                           306 (2.3)        Nausea                                   235 (2.0)        Thrombocytopenia                         123 (1.6)      Acute myeloid leukemia                         15 (2.3)
  Thrombocytopenia                               249 (1.9)        Platelet count decreased                 234 (2.0)        Hypersensitivity                         119 (1.5)      Sepsis                                         14 (2.1)
  Bone marrow failure                            244 (1.8)        White blood cell count decreased         218 (1.8)        Sepsis                                   102 (1.3)      Anaphylactoid reaction                         13 (2.0)
  Renal impairment                               239 (1.8)        Vomiting                                 204 (1.7)        Diarrhea                                 101 (1.3)      Myelodysplastic syndrome                       13 (2.0)
  Interstitial lung disease                      227 (1.7)        Anaphylactoid reaction                   187 (1.6)        Anorexia                                 89 (1.1)       Leukopenia                                     12 (1.8)
  Acute kidney injury                            201 (1.5)        Febrile neutropenia                      172 (1.5)        Nausea                                   84 (1.1)       Anaphylactic reaction                          10 (1.5)
  Vomiting                                       184 (1.4)        Anaphylactic reaction                    130 (1.1)        Disseminated intravascular coagulation   80 (1.0)       Anemia                                         10 (1.5)
  Stomatitis                                     183 (1.4)        Pyrexia                                  121 (1.0)        Hepatic function abnormal                79 (1.0)       Acute kidney injury                            9 (1.4)
  Hyponatremia                                   158 (1.2)        Hyperammonemia                           108 (0.9)        Leukopenia                               79 (1.0)       Pancytopenia                                   9 (1.4)
  Pancytopenia                                   155 (1.2)        Disseminated intravascular coagulation   107 (0.9)        Acute myeloid leukemia                   78 (1.0)       Renal impairment                               8 (1.2)
  Pneumonia                                      152 (1.1)        Pneumonia                                103 (0.9)        Myelodysplastic syndrome                 78 (1.0)       Hypersensitivity                               7 (1.1)
  Sepsis                                         151 (1.1)        Hypersensitivity                         91 (0.8)         Pyrexia                                  78 (1.0)       Pneumonia                                      7 (1.1)
  Inappropriate antidiuretic hormone secretion   150 (1.1)        Stomatitis                               86 (0.7)         Stomatitis                               72 (0.9)       Disseminated intravascular coagulation         6 (0.9)
  Anaphylactic shock                             135 (1.0)        Feebleness                               84 (0.7)         Anaphylactic reaction                    71 (0.9)       Septic shock                                   6 (0.9)
  Disseminated intravascular coagulation         118 (0.9)        Acute kidney injury                      83 (0.7)         Hemoglobin decreased                     64 (0.8)       Pneumocystis jirovecii pneumonia               5 (0.8)
  Pyrexia                                        102 (0.8)        Dyspnoea                                 78 (0.7)         Pancytopenia                             64 (0.8)       Hemoglobin decreased                           5 (0.8)
  Cerebral infarction                            87 (0.7)         Dehydration                              64 (0.5)         Vomiting                                 64 (0.8)       Gastrointestinal hemorrhage                    5 (0.8)
  Myelodysplastic syndrome                       86 (0.6)         Sepsis                                   62 (0.5)         Rash                                     59 (0.8)       Neutropenic infection                          5 (0.8)
  Renal disorder                                 85 (0.6)         Ileus                                    57 (0.5)         Liver disorder                           44 (0.6)       Inappropriate antidiuretic hormone secretion   5 (0.8)
  Hepatic function abnormal                      78 (0.6)         Cerebral infarction                      50 (0.4)         Cerebral infarction                      44 (0.6)       Vomiting                                       5 (0.8)
  Feebleness                                     76 (0.6)         Altered state of consciousness           48 (0.4)         Septic shock                             41 (0.5)       Nausea                                         4 (0.6)
  Acute myeloid leukemia                         70 (0.5)         Gastrointestinal perforation             46 (0.4)         Neuropathy peripheral                    40 (0.5)       Pleural effusion                               4 (0.6)
  Renal failure                                  68 (0.5)         Anaemia                                  44 (0.4)         Shock                                    39 (0.5)       Anorexia                                       4 (0.6)
  Septic shock                                   65 (0.5)         Enterocolitis                            39 (0.3)         Acute kidney injury                      38 (0.5)       Pericardial effusion                           4 (0.6)
  Dehydration                                    60 (0.5)         Abdominal pain                           38 (0.3)         Pneumonitis                              37 (0.5)       Posterior reversible encephalopathy syndrome   3 (0.5)
  Gastric perforation                            56 (0.4)         Fatigue                                  37 (0.3)         Pulmonary embolism                       36 (0.5)       Infection                                      3 (0.5)
  Pulmonary embolism                             55 (0.4)         Aspartate aminotransferase increased     36 (0.3)         Renal impairment                         35 (0.4)       Acute respiratory distress syndrome            3 (0.5)
  Blood creatinine increased                     52 (0.4)         Hepatic function abnormal                36 (0.3)         Cardiac failure                          33 (0.4)       Respiratory failure                            3 (0.5)
  Infection                                      50 (0.4)         Peritonitis                              34 (0.3)         Arthralgia                               31 (0.4)       Sudden death                                   3 (0.5)
  Anaphylactic reaction                          48 (0.4)         Blood creatinine increased               33 (0.3)         Ileus                                    30 (0.4)       Pneumonitis                                    3 (0.5)

###### 

Number of reports and the ROR for renal impairment by platinum-based compounds.

![](10.1177_2050312118772475-table2)

  Drug          Total     Case     ROR (95% CI)
  ------------- --------- -------- ----------------
  Total         430,587   14,872   
  Cisplatin     7046      614      2.7 (2.5--3.0)
  Oxaliplatin   6834      135      0.6 (0.5--0.7)
  Carboplatin   4312      125      0.8 (0.7--1.0)
  Nedaplatin    400       18       1.3 (0.8--2.1)

ROR: reporting odds ratio; CI: confidence interval.

The median (lower--upper quartile) onset time of RI after the use of platinum-based compounds was 6.0--8.0 days ([Table 3](#table3-2050312118772475){ref-type="table"} and [Figure 2](#fig2-2050312118772475){ref-type="fig"}). We noted that 58.9% (313 out of 532 cases) of RI events were observed within 7 days of drug administration; however, 41.1% were reported after 7 days of drug administration. The WSP β and 95% CI upper limit of oxaliplatin were \<1, indicating a significant association between oxaliplatin and RI.

###### 

The medians and Weibull parameter of each drug for renal impairment.

![](10.1177_2050312118772475-table3)

  Drugs         Case (*n*)   Median (day) (25%--75%)   Scale parameter        Shape parameter
  ------------- ------------ ------------------------- ---------------------- -------------------
  Cisplatin     358          6.0 (3.0--11.0)           10.52 (9.38--11.77)    0.99 (0.92--1.06)
  Oxaliplatin   96           7.0 (2.3--15.8)           13.90 (10.65--18.01)   0.82 (0.70--0.95)
  Carboplatin   67           8.0 (4.0--15.0)           11.83 (9.10--15.25)    1.02 (0.84--1.21)
  Nedaplatin    11           7.0 (3.0--28.0)           14.60 (6.96--29.09)    1.09 (0.61--1.73)

CI: confidence interval.

![Histogram and Weibull shape parameter of renal impairment for (a) cisplatin (β = 0.99 (95% CI: 0.92--1.06)), (b) oxaliplatin (β = 0.82 (95% CI: 0.70--0.95)), (c) carboplatin (β = 1.02 (95% CI: 0.84--1.21)), and (d) nedaplatin (β = 1.09 (95% CI: 0.61--1.73)).](10.1177_2050312118772475-fig2){#fig2-2050312118772475}

We evaluated the possible associations between RI and demographic data. The result of the mining algorithm was a set of 31 rules ([Table 4](#table4-2050312118772475){ref-type="table"}). The *support*, *confidence*, and *lift* of each association are summarized in [Table 4](#table4-2050312118772475){ref-type="table"} and illustrated in [Figure 3](#fig3-2050312118772475){ref-type="fig"}. The association rules up to 31 positions in descending order of the *lift* are also shown in [Table 4](#table4-2050312118772475){ref-type="table"}. The association rules of {cisplatin} → {RI} and {cisplatin, male} → {RI} demonstrated high support values ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[24\] and id \[19\]; [Figure 3](#fig3-2050312118772475){ref-type="fig"}). The association rule of {cisplatin, male} → {RI} demonstrated approximately four times the score for *support* of females ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[31\]). In addition, the association rule of {aprepitant, cisplatin} → {RI} demonstrated the highest *lift* score ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[1\]). The association rules of {cisplatin, hypertension} → {RI} and {cisplatin, diabetes mellitus} → {RI} demonstrated high scores for *lift* ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[2\] and id \[4\]). Furthermore, the association rules of {cisplatin, furosemide} → {RI}, {cisplatin, loxoprofen sodium hydrate} → {RI}, and {cisplatin, pemetrexed sodium hydrate} → {RI} demonstrated high scores for *lift* ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[7\], id \[9\], and id \[10\]). The association rules of {50--59 years of age, cisplatin} → {RI}, {60--69 years of age, cisplatin} → {RI}, and {70--79 years of age, cisplatin} → {RI} gradually demonstrated high scores for *lift* with increasing age ([Table 4](#table4-2050312118772475){ref-type="table"}, id \[16\], id \[23\], and id \[28\]).

###### 

Association parameters of rules (sort by lift).

![](10.1177_2050312118772475-table4)

  id       lhs^[a](#table-fn4-2050312118772475){ref-type="table-fn"}^       rhs^[b](#table-fn5-2050312118772475){ref-type="table-fn"}^   Support   Confidence   Lift
  -------- ------------------------------------------------------------ --- ------------------------------------------------------------ --------- ------------ ------
  \[1\]    {aprepitant, cisplatin}                                      →   {renal impairment}                                           0.00018   0.15         4.28
  \[2\]    {cisplatin, hypertension}                                    →   {renal impairment}                                           0.00024   0.14         3.86
  \[3\]    {cisplatin, mecobalamin}                                     →   {renal impairment}                                           0.00016   0.13         3.75
  \[4\]    {cisplatin, diabetes mellitus}                               →   {renal impairment}                                           0.00013   0.13         3.58
  \[5\]    {cisplatin, diarrhea}                                        →   {renal impairment}                                           0.00014   0.12         3.55
  \[6\]    {cisplatin, retinol-calciferol}                              →   {renal impairment}                                           0.00020   0.12         3.45
  \[7\]    {cisplatin, furosemide}                                      →   {renal impairment}                                           0.00018   0.11         3.13
  \[8\]    {oxycodone hydrochloride hydrate, cisplatin}                 →   {renal impairment}                                           0.00010   0.11         3.10
  \[9\]    {cisplatin, loxoprofen sodium hydrate}                       →   {renal impairment}                                           0.00012   0.10         2.94
  \[10\]   {cisplatin, pemetrexed sodium hydrate}                       →   {renal impairment}                                           0.00026   0.10         2.94
  \[11\]   {cisplatin, famotidine}                                      →   {renal impairment}                                           0.00013   0.10         2.86
  \[12\]   {cisplatin, dexamethasone}                                   →   {renal impairment}                                           0.00011   0.10         2.86
  \[13\]   {cisplatin, hepatic cancer}                                  →   {renal impairment}                                           0.00012   0.09         2.69
  \[14\]   {granisetron hydrochloride, cisplatin}                       →   {renal impairment}                                           0.00021   0.09         2.61
  \[15\]   {cisplatin, dexamethasone sodium phosphate}                  →   {renal impairment}                                           0.00027   0.09         2.55
  \[16\]   {70--79 years of age, cisplatin}                             →   {renal impairment}                                           0.00048   0.09         2.51
  \[17\]   {cisplatin, gastric cancer}                                  →   {renal impairment}                                           0.00021   0.09         2.47
  \[18\]   {cisplatin, febrileneutropenia}                              →   {renal impairment}                                           0.00011   0.08         2.43
  \[19\]   {cisplatin, male}                                            →   {renal impairment}                                           0.00122   0.08         2.40
  \[20\]   {cisplatin, white blood cell count decreased}                →   {renal impairment}                                           0.00012   0.08         2.35
  \[21\]   {cisplatin, unknown}                                         →   {renal impairment}                                           0.00011   0.08         2.30
  \[22\]   {cisplatin, anorexia}                                        →   {renal impairment}                                           0.00010   0.08         2.26
  \[23\]   {60--69 years of age, cisplatin}                             →   {renal impairment}                                           0.00054   0.07         2.13
  \[24\]   {cisplatin}                                                  →   {renal impairment}                                           0.00158   0.07         2.10
  \[25\]   {cisplatin, fluorouracil}                                    →   {renal impairment}                                           0.00025   0.07         2.01
  \[26\]   {cisplatin, platelet count decreased}                        →   {renal impairment}                                           0.00010   0.07         1.99
  \[27\]   {cisplatin, tegafur-gimeracil-oteracil potassium}            →   {renal impairment}                                           0.00026   0.07         1.91
  \[28\]   {50--59 years of age, cisplatin}                             →   {renal impairment}                                           0.00022   0.06         1.79
  \[29\]   {etoposide, carboplatin}                                     →   {renal impairment}                                           0.00013   0.06         1.68
  \[30\]   {cisplatin, magnesium oxide}                                 →   {renal impairment}                                           0.00011   0.05         1.56
  \[31\]   {cisplatin, female}                                          →   {renal impairment}                                           0.00032   0.05         1.50

lhs: left-hand side; rhs: right-hand side.

lhs of rule (antecedents).

rhs (consequents).

![Association rules for renal impairment (RI) based on JADER database from April 2004 to November 2016. Plot represents items and rules as vertices connected with directed edges. Relation parameters are typically added to the plot as labels on the edges or by varying the color or width of the arrows indicating the edges.](10.1177_2050312118772475-fig3){#fig3-2050312118772475}

Discussion {#section8-2050312118772475}
==========

The RI signal was detected for cisplatin but not for the other platinum-based compounds in the JADER database. This result agrees with those of previous studies.^[@bibr28-2050312118772475][@bibr29-2050312118772475]--[@bibr30-2050312118772475]^ Approximately 40% of the RI cases were observed 1 week after treatment in the clinical settings. This indicates that health professionals should closely monitor patients for several weeks for RI incidence following treatment with platinum-based compounds.

The upper limit of the 95% CI of ROR for oxaliplatin was \<1. We do not have a conclusive explanation for this result. However, the upper limit of the 95% CI of WSP β was \<1 ([Table 3](#table3-2050312118772475){ref-type="table"} and [Figure 2](#fig2-2050312118772475){ref-type="fig"}), and the hazard was considered to decrease over time (initial failure type; [Table 3](#table3-2050312118772475){ref-type="table"}). We considered that the risk of RI by oxaliplatin should not be ignored:

The association rule mining revealed that the incidence of RI with primary disease--related items such as hypertension or diabetes mellitus was high because of the *lift* values of two combined items. An association between RI and hypertension or diabetes mellitus is commonly accepted.^[@bibr31-2050312118772475],[@bibr32-2050312118772475]^ Diabetes mellitus and cardiovascular diseases such as hypertension increase the risk of severe acute kidney injury.^[@bibr31-2050312118772475]^ Moreover, diabetes mellitus and high blood pressure are the first and second leading causes, respectively, of kidney failure.^[@bibr32-2050312118772475]^ The association rule of {cisplatin, diarrhea} → {RI} demonstrated high scores for *lift*. Late-onset diarrhea is one of the AEs following cisplatin use,^[@bibr33-2050312118772475]^ which often causes extensive gastrointestinal AEs that might lead to magnesium depletion through anorexia and diarrhea. Magnesium depletion may also enhance cisplatin-induced nephrotoxicity.^[@bibr34-2050312118772475],[@bibr35-2050312118772475]^ Therefore, we believe that primary diseases such as diabetes mellitus, hypertension, and diarrhea might be associated with the risk of cisplatin-induced nephrotoxicity.

The *lift* values of RI with concomitant use of drugs such as furosemide, loxoprofen, or pemetrexed were also high. Co-administration of furosemide or saline hydration and mannitol diuresis are often required to minimize cisplatin-induced nephrotoxicity.^[@bibr35-2050312118772475]^ These interventions reduce both cisplatin concentration in the renal tubules and the duration of exposure of renal tubular epithelial cells to cisplatin.^[@bibr36-2050312118772475]^ In contrast, the risk of enhanced nephrotoxicity with concurrent furosemide intake has been reported and is stated on the package insert of cisplatin.^[@bibr37-2050312118772475],[@bibr38-2050312118772475]^ The National Comprehensive Cancer Network reported that total furosemide dose is associated with the development of renal toxicity and recommends the use of mannitol for the prevention of cisplatin-induced nephrotoxicity.^[@bibr37-2050312118772475],[@bibr39-2050312118772475],[@bibr40-2050312118772475]^ Conversely, nonsteroidal anti-inflammatory drugs can induce kidney injury, including hemodynamically mediated acute kidney injury.^[@bibr41-2050312118772475]^ Co-administration of cisplatin and other antineoplastic agents is thought to be a risk factor for cisplatin-induced acute kidney injury.^[@bibr42-2050312118772475]^ Pemetrexed is an antifolate antineoplastic agent that can be used alone or in combination with other antineoplastic drugs such as cisplatin.^[@bibr43-2050312118772475],[@bibr44-2050312118772475]^ As pemetrexed causes renal tubular toxicity, the association rule for combined use of cisplatin and pemetrexed suggested a risk of RI.^[@bibr45-2050312118772475]^ This indicates that co-administration of cisplatin and furosemide, loxoprofen, or pemetrexed may increase the risk of RI. Therefore, patients who co-administered these drugs should be carefully monitored.

The findings of several clinical studies indicate that the incidence of cisplatin-induced nephrotoxicity is higher in older patients than in younger patients.^[@bibr34-2050312118772475]^ The results of the association rule mining confirmed age as a risk factor for cisplatin-induced nephrotoxicity.

The *lift* values of RI with other co-administered drugs such as aprepitant, mecobalamin (vitamin B~12~), or dexamethasone were also high. However, we are unable to conclusively explain these association rules. Aprepitant and dexamethasone are commonly administered to reduce vomiting caused by cisplatin.^[@bibr4-2050312118772475]^ Furthermore, mecobalamin and folic acid are commonly administered as prophylactics to reduce pemetrexed-induced hematologic and gastrointestinal toxicities.^[@bibr46-2050312118772475]^ It has been reported that mecobalamin does not affect the plasma clearance of pemetrexed.^[@bibr47-2050312118772475]^ The *lift* scores related to aprepitant, mecobalamin, and dexamethasone might be apparent. Therefore, we believe that the possibility of RI due to co-administration of aprepitant, mecobalamin, or dexamethasone during treatment with pemetrexed is low.

The risk of developing nephrotoxicity has been reported to be higher in women than in men.^[@bibr34-2050312118772475],[@bibr37-2050312118772475],[@bibr48-2050312118772475]^ In contrast, several reports indicate that women are at a lower risk of developing cisplatin-induced nephrotoxicity than men.^[@bibr49-2050312118772475]^ The *lift* of {cisplatin, male} → {RI} was higher than that of {cisplatin, female} → {RI}. The reason for this result is unclear.

Our study had some limitations that are worth mentioning. First, the JADER database does not contain detailed background information on medical history (e.g. treatment regimen). Second, SRS has several limitations, including underreporting, overreporting, missing data, comorbidities, and the exclusion of healthy individuals as a reference group.^[@bibr11-2050312118772475]^ Third, in the association rule mining, the researcher determined the parameters (*support*, *confidence*, and *maxlen*) according to their dataset and the purpose of research. The values of these parameters in studies conducted by several research reports vary.^[@bibr18-2050312118772475][@bibr19-2050312118772475][@bibr20-2050312118772475][@bibr21-2050312118772475]--[@bibr22-2050312118772475]^ Because of the high *support* and *confidence* value, we consider that important association rules related to RI and platinum-based compounds have not been overlooked in our study. However, these parameters are not strict criteria. Therefore, further epidemiological studies might be required to confirm these results.

Conclusion {#section9-2050312118772475}
==========

This study is the first to evaluate the correlation between platinum-based compounds and RI using ROR, time-to-onset analysis, and association rule mining technique based on the JADER database. Despite the inherent limitations of SRS, we have shown the potential risk of RI during the clinical use of cisplatin. The present analysis demonstrates that the incidence of RI associated with cisplatin use should be closely monitored when patients are hypertensive or diabetic and are co-administered furosemide, loxoprofen, or pemetrexed. We believe that the data presented in this study will help healthcare professionals improve the care of patients undergoing chemotherapy with platinum-based compounds.
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